Evidence map›Paper›PMID 37451357›Full record

ArticleNeuroscience letters2023

Mini-review: Enteric glial cell reactions to inflammation and potential therapeutic implications for GI diseases, motility disorders, and abdominal pain.

Andromeda Linan-Rico, Fernando Ochoa-Cortes, Reiner Schneider, Fievos L Christofi

Open access · greenAbstract read
In one paragraph

Article in Neuroscience letters, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.

0numbers the graph read from it
0cells of the map it votes in
29citing papers in PubMed
8.6field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

29 citing papers in PubMed, 27 citations in OpenAlex.

  1. Trial
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Review
  9. Review
  10. Review
  11. Article
  12. Article
  13. Review
  14. Introducing Enteric Glial Cells.Methods in molecular biology (Clifton, N.J.) · 2026
    Article
  15. Article
  16. Enteric nervous system as a therapeutic target in gastrointestinal disorders.World journal of gastrointestinal pharmacology and therapeutics · 2025
    Article
  17. Article
  18. Article
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 3 institutions in 2 countries.

Andromeda Linan-RicoUniversity Center for Biomedical Research, National Council of Humanities Science and Technology (CONAHCYT)-University of Colima, Colima, Mexico.
Fernando Ochoa-CortesEscuela Superior de Huejutla, Universidad Autónoma del Estado de Hidalgo, Hidalgo, México.
Reiner SchneiderUniversity Clinics Bonn, Department of Surgery, Bonn, Germany.
Fievos L ChristofiDepartment of Anesthesiology, The Ohio State University Wexner Medical Center, Columbus, OH, USA. Electronic address: fedias.christofi@osumc.edu.
The Ohio State University Wexner Medical Center · USUniversidad Autónoma del Estado de Hidalgo · MXUniversidad de Colima · MX

Funding

Enteric glial ETBR signaling in postoperative ileusR01DK125809 · NIDDK · OHIO STATE UNIVERSITY · PI CHRISTOFI, FEDIAS LEONTIOU · 2020 to 2023
$1.6M
Human enteric glia: A novel target for motility and postoperative ileusR01DK113943 · NIDDK · OHIO STATE UNIVERSITY · PI CHRISTOFI, FEDIAS LEONTIOU, GRIDER, JOHN R · 2017 to 2019
$1.4M
NIDDK NIH HHS R01 DK113943NIDDK NIH HHS R01 DK125809
6 · The paper itself

Abstract

Enteric glial cells are emerging as critical players in the regulation of intestinal motility, secretion, epithelial barrier function, and gut homeostasis in health and disease. Enteric glia react to intestinal inflammation by converting to a 'reactive glial phenotype' and enteric gliosis, contributing to neuroinflammation, enteric neuropathy, bowel motor dysfunction and dysmotility, diarrhea or constipation, 'leaky gut', and visceral pain. The focus of the minireview is on the impact of inflammation on enteric glia reactivity in response to diverse insults such as intestinal surgery, ischemia, infections (C. difficile infection, HIV-Tat-induced diarrhea, endotoxemia and paralytic ileus), GI diseases (inflammatory bowel diseases, diverticular disease, necrotizing enterocolitis, colorectal cancer) and functional GI disorders (postoperative ileus, chronic intestinal pseudo-obstruction, constipation, irritable bowel syndrome). Significant progress has been made in recent years on molecular pathogenic mechanisms of glial reactivity and enteric gliosis, resulting in enteric neuropathy, disruption of motility, diarrhea, visceral hypersensitivity and abdominal pain. There is a growing number of glial molecular targets with therapeutic implications that includes receptors for interleukin-1 (IL-1R), purines (P2X2R, A2BR), PPARα, lysophosphatidic acid (LPAR1), Toll-like receptor 4 (TLR4R), estrogen-β receptor (ERβ) adrenergic α-

Indexed as

Clostridioides difficileEnteric Nervous SystemGastrointestinal DiseasesIntestinal Pseudo-ObstructionAbdominal PainConstipationDiarrheaGastrointestinal MotilityGliosisHumansInfant, NewbornInflammationNeurogliaAbdominal painEnteric gliaGI diseasesGI disordersMotility disordersNeuroinflammation

Identifiers

PMID37451357
PMCPMC10952371
OpenAlexW4384008990

What Socratic holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.